Xtandi

Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients
Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients
Seeking Alpha
Pfizer
Astellas
Xtandi
prostate cancer
clinical trials
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi
US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi
Fierce Pharma
Pfizer
Astellas
Xtandi
prostate cancer
drug pricing
NIH
march-in rights
Flag link:
ASCO GU: Pfizer touts Talzenna's strong showing in PARP prostate cancer battle with AstraZeneca, J&J
ASCO GU: Pfizer touts Talzenna's strong showing in PARP prostate cancer battle with AstraZeneca, J&J
Fierce Pharma
ASCO GU
Pfizer
Astellas
Xtandi
prostate cancer
Flag link:
Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug
Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug
Stat
cancer
oncology
Joe Biden
Astellas
Xtandi
prostate cancer
Flag link:
Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Endpoints
Pfizer
Xtandi
Talzenna
PARP inhibitors
Medivation
clinical trials
prostate cancer
Flag link:
'March-in' battles heat up as nonprofits petition HHS on 6 drugs as earlier petition awaits decision
'March-in' battles heat up as nonprofits petition HHS on 6 drugs as earlier petition awaits decision
Endpoints
HHS
Bayh-Dole Act
drug pricing
Pfizer
Gilead Sciences
Xtandi
Paxlovid
Epclusa
Descovy
insulin
Flag link:
March-in campaign on Pfizer's prostate cancer med Xtandi gets congressional backing. Will it matter?
March-in campaign on Pfizer's prostate cancer med Xtandi gets congressional backing. Will it matter?
Fierce Pharma
Pfizer
Astellas
prostate cancer
Xtandi
NIH
Flag link:
ESMO: Pfizer, Astellas' latest Xtandi survival data may shore up prostate cancer lead over J&J
ESMO: Pfizer, Astellas' latest Xtandi survival data may shore up prostate cancer lead over J&J
Fierce Pharma
ESMO
Pfizer
Astellas
Xtandi
prostate cancer
clinical trials
Flag link:
ASCO: Pfizer, Astellas show Xtandi helps early prostate cancer patients live longer
ASCO: Pfizer, Astellas show Xtandi helps early prostate cancer patients live longer
Fierce Pharma
ASCO 2020
Pfizer
Astellas
Xtandi
castration-resistant prostate cancer
Flag link:
Pfizer and Astellas Report Positive OS Data in Prostate Cancer Study
Pfizer and Astellas Report Positive OS Data in Prostate Cancer Study
BioSpace
Pfizer
Astellas
prostate cancer
metastatic castration-resistant prostate cancer
Xtandi
Flag link:
Pfizer, Astellas' Xtandi matches J&J's rival Erleada with new prostate cancer nod
Pfizer, Astellas' Xtandi matches J&J's rival Erleada with new prostate cancer nod
Fierce Pharma
Pfizer
Astellas
Xtandi
prostate cancer
JNJ
Erleada
FDA
Flag link:
Pfizer, Astellas rocket toward broader Xtandi use with FDA 'priority' tag
Pfizer, Astellas rocket toward broader Xtandi use with FDA 'priority' tag
Fierce Pharma
Pfizer
Astellas
Xtandi
prostate cancer
FDA
priority review
Flag link:
ASCO: Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approval
ASCO: Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approval
Fierce Pharma
Pfizer
Astellas
Xtandi
prostate cancer
ASCO 2019
Flag link:
Pfizer, Astellas chase new Xtandi nod with big survival numbers in prostate cancer
Pfizer, Astellas chase new Xtandi nod with big survival numbers in prostate cancer
Fierce Pharma
Xtandi
Astellas
Pfizer
hormone-sensitive prostate cancer
Flag link:
Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer
Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer
CP Wire
Astellas
Pfizer
Xtandi
prostate cancer
metastatic prostate cancer
Flag link:
Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer
Astellas
Pfizer
Xtandi
prostate cancer
metastatic prostate cancer
Flag link:
Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214
Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214
BioCentury
Pfizer
Nektar Therapeutics
NKTR-214
Xtandi
Talzenna
Bavencio
prostate cancer
Flag link:
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
Yahoo/Zacks.com
prostate cancer
JNJ
Zytiga
Erleada
Pfizer
Astellas
Xtandi
AbbVie
Lupron
Endocyte
Lu-PSMA-617
Flag link:

Pages